Yahoo Finance • 2 months ago
Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the us... Full story
Yahoo Finance • 3 months ago
Myriad Genetics, Inc. SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issu... Full story
Yahoo Finance • 4 months ago
On August 21, 2024, Margaret Ancona, Senior Vice President, Chief of Staff at Myriad Genetics Inc (NASDAQ:MYGN), executed a sale of 11,538 shares of the company. Following this transaction, the insider now owns 79,366 shares of Myriad Gene... Full story
Yahoo Finance • 4 months ago
Myriad Genetics, Inc. SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor... Full story
Yahoo Finance • 7 months ago
On May 13, 2024, Director Lee Newcomer sold 6,200 shares of Myriad Genetics Inc (NASDAQ:MYGN) as reported in a recent SEC Filing. The transaction occurred at a price of $25.3 per share. Warning! GuruFocus has detected 4 Warning Signs with... Full story
Yahoo Finance • 8 months ago
Myriad Genetics, Inc. Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic tes... Full story
Yahoo Finance • last year
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gend... Full story
Yahoo Finance • last year
SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (... Full story
Yahoo Finance • last year
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference... Full story
Yahoo Finance • last year
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the pricing of an upsized underwritten publi... Full story
Yahoo Finance • last year
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that it plans to make a public offering of $... Full story
Yahoo Finance • last year
Myriad Genetics, Inc. Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year growth. In the third... Full story
Yahoo Finance • last year
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December... Full story
Yahoo Finance • last year
Partnership covers development of lab-developed and distributable kit-based companion diagnostic testsCombined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion... Full story
Yahoo Finance • last year
Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen Begleittests auf Kit-Basis // Vereinte Stärken in den Bereichen Assay-Entwicklung, klinische Tests und regulatorische Zulassungen bie... Full story
Yahoo Finance • last year
SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health hist... Full story
Yahoo Finance • last year
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN... Full story
Yahoo Finance • last year
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key... Full story
Yahoo Finance • last year
SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the... Full story
Yahoo Finance • last year
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023... Full story